meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - maintenance (M)
2
pancreatic ductal adenocarcinoma
PIK3CA-related overgrowth spectrum
prostate cancer (PC)
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab plus SoC
nivolumab based treatment
poly ADP-ribose polymerase (PARP) inhibitor
rucaparib
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs poly ADP-ribose polymerase (PARP) inhibitor
vs rucaparib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
avelumab based treatment
avelumab plus SoC
Comparator:
vs Standard of Care (SoC);
Risk of bias:
low;
some concerns;
high;
NA;